24 articles for thisTarget
The following articles (labelled with PubMed ID or TBD) are for your review
PMID
Data
Article Title
Organization
Benzylamide antagonists of protease activated receptor 2 with anti-inflammatory activity.
The University of Queensland
Discovery of 2-aryloxy-4-amino-quinazoline derivatives as novel protease-activated receptor 2 (PAR2) antagonists.
Yonsei University
Inhibitors of the PAR-2 Signaling Pathway May Treat Pain and Inflammation.
Therachem Research Medilab (India)
Further studies at neuropeptide s position 5: discovery of novel neuropeptide S receptor antagonists.
National Institute of Neuroscienc
Novel agonists and antagonists for human protease activated receptor 2.
The University of Queensland
Screening Ultra-Large Encoded Compound Libraries Leads to Novel Protein-Ligand Interactions and High Selectivity.
Astrazeneca
Privileged heterocycles for DNA-encoded library design and hit-to-lead optimization.
Chinese Academy of Sciences
Imidazo[1,2-b]pyridazine as privileged scaffold in medicinal chemistry: An extensive review.
Universite de Tours
Synthesis and evaluation of novel and potent protease activated receptor 4 (PAR4) antagonists based on a quinazolin-4(3H)-one scaffold.
China Pharmaceutical University
Synthesis and initial pharmacology of dual-targeting ligands for putative complexes of integrin αVβ3 and PAR2.
Marquette University
Discovery of Novel Nonpeptidic PAR2 Ligands.
Friedrich-Alexander University Erlangen-N£Rnberg (Fau)
Design and Evaluation of Heterobivalent PAR1-PAR2 Ligands as Antagonists of Calcium Mobilization.
Marquette University
Small Molecule Allosteric Modulators of G-Protein-Coupled Receptors: Drug-Target Interactions.
Shanghai Jiao Tong University
A refined agonist pharmacophore for protease activated receptor 2.
University of Queensland
Characterization of Protease-Activated Receptor (PAR) ligands: Parmodulins are reversible allosteric inhibitors of PAR1-driven calcium mobilization in endothelial cells.
Marquette University
Isoxazole-tethered diarylheptanoid analogs: Discovery of a new drug-like PAR2 antagonist.
Advinus Therapeutics
Heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same
Daewoong Pharmaceutical
Isoindolinone inhibitors of the MDM2-p53 interaction having anticancer activity
Astex Therapeutics